News

Dr. Kate Knobil joins the biotech as it looks to combat a viral infection that can be dangerous to patients with the lung ...
As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...
Puma Biotech (PBYI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose ...
As a descendant of an Indigenous Amazonian tribe, Maria Astolfi was concerned about research she conducted as a graduate ...
Azithromycin has been widely evaluated for its efficacy against COVID-19. The study by Timothy S C Hinks and colleagues1 adds value to the current literature, and we would like to share our comments.
or biotech startup Treeline Biosciences find new drug candidates by simulating molecules. Sign up here. Its software was originally written with central processor units, or CPUs, in mind during an ...
a Kansas City-based biotech company, led to the company winning a grant for development of a new HIV therapy. What it takes for KC pharma companies to face the 'valley of death' KC takes its shot ...
ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...
I don’t think it’s entirely bad. Especially in biopharma, I think it’s rational for a biotech to be private for longer until the drug is showing meaningful human data. Twenty, thirty years ...
The biotech previously disclosed AlpineBrook convertible notes. NKGen said Song has invested to try to accelerate its phase 2 trial, reduce its payables and cover the expenses it incurs as a ...
Unity’s restructuring comes along with 36-week results from its phase 2b Aspire trial that ... co-founder and CEO Trevor Martin confirmed with Fierce Biotech in an emailed statement.